Gofar Stock(SH:600538)2026-01-16 10:00Revenue Projections - The company expects to achieve approximately CNY 330 million in revenue for the fiscal year 2025, with no significant unrelated business income included [3]. - In 2024, the company reported revenue of CNY 340.46 million and a net loss of CNY -93.85 million [5]. - The decline in revenue is primarily due to intensified market competition, leading to a 10% decrease in revenue and a 3% drop in gross margin for the wholly-owned subsidiary Guangzhou Gaosheng Biotechnology Co., Ltd. [6]. - The pharmaceutical plant of Beihai Guofa Chuanshan Bio Co., Ltd. experienced a 30% decline in revenue due to maintenance of the eye drop production line and delays in sales recovery [6]. Net Loss Projections - The projected net loss attributable to the parent company for 2025 is around CNY -85 million, representing a decrease in loss of approximately CNY 9 million or 10% compared to the previous year [4]. - The net loss attributable to the parent company, after excluding non-recurring gains and losses, is expected to be around CNY -85.5 million, a reduction of approximately CNY 4.5 million compared to the previous year [4]. Goodwill Impairment - The company anticipates a goodwill impairment provision of approximately CNY 62 million due to the acquisition of Guangzhou Gaosheng Biotechnology Co., Ltd. [6]. Financial Reporting - The financial data provided is preliminary and has not been audited by a registered accountant, and the final figures will be disclosed in the audited annual report for 2025 [8].